In breast cancer, PLC-β1 (48) and PLC-β2 (49) are abnormally overexpressed, driving tumor progression by enhancing proliferation and migration. Furthermore, PLC-γ1 is associated with poorly and moderately differentiated breast cancers, and its overexpression correlates with increased risk of metastasis and recurrence (50). Here, PLCB2 is linked to neoplasm.